• Research & Development
• Pipeline
• Research & Clinical Trials
• Phases of Development
• Post Marketing Commitments
  • What is a PMC?
  • U.S. Medicine Specific PMCs
  • U.S. PMC Summary
  • FAQs
  • Glossary
• R&D Locations
• Licensing
• Investigator-Initiated Research
• Compound Transfer Program

Summary Information of Listed U.S. Post Marketing Commitments

To review summary information of Pfizer U.S. post marketing medicines, select from the following:

• Total Listed U.S. Post Marketing Commitments (all statuses, including Fulfilled, Released, and Terminated)
• Total Active U.S. Post Marketing Commitments (includes Pending, On-going, Delayed, and Submitted)
• U.S. Post Marketing Commitments by Status
• U.S. Post Marketing Commitments by Type

Total Listed U.S. Post Marketing Commitments

Pfizer post marketing commitments as of	11/05/2009
Listed PMCs (all statuses, including Fulfilled, Released, and Terminated)	143

Total Active U.S. Post Marketing Commitments

Pfizer post marketing commitments as of	11/05/2009
Active PMCs (Pending, On-going, Delayed, and Submitted)	61

U.S. Post Marketing Commitments by Status

Pfizer post marketing commitments as of	11/05/2009
Pending	10
On-going	19
Delayed	4
Terminated	1
Submitted	28
Fulfilled	72
Released	9

To review individual commitments of specific status, search Medicine-specific U.S. Post Marketing Commitments.

Top

U.S. Post Marketing Commitments by Type

Pfizer post marketing commitments as of	11/05/2009
Clinical trial	75
Pre-clinical	14
Safety	16
Pediatric	20
Special population	7
New dosage form/strength	0
Other	11

To review individual commitments of specific type, search Medicine-specific U.S. Post Marketing Commitments.

Top

About the Information Posted on This Web Site:

This Web site contains information about Pfizer’s U.S. pharmaceutical post marketing commitments. The post marketing commitments listed here include pre-clinical, clinical and epidemiological studies or testing agreed to by Pfizer (including its subsidiaries) and the FDA, and are used to gather additional information about the safety, efficacy, or use of approved Pfizer medicines. This Web site provides the current status of Pfizer post marketing commitments listed on the FDA Web site and includes post marketing commitments established for Pfizer medicines in the U.S. since August 1, 2000. New post marketing commitments will be listed on this Web site as they are established. Released or completed post marketing commitments will be removed from the site.

This Web site does not contain technical chemistry, manufacturing and control (CMC) commitments, or commitments for medicines where Pfizer is not the FDA license holder. Information about Pfizer’s post marketing commitments to the U.S. FDA is believed to be correct at the time that the information is posted, and is subject to change as progress is made in fulfilling the commitments.

This Web site is updated monthly. The status of post marketing commitments shown on the FDA Web site may differ from information displayed on this site, due to differences in the timing of updates made to the FDA Web site. The number of commitments on the two sites may also differ, due to the frequency of such updates and/or due to multiple reporting of single commitments on the FDA Web site.